Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan

Li Min Huang, Tzou Yien Lin, Christine Juergens

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.In this double-blind, multicenter study, healthy children were randomly assigned to receive PCV13 (n= 84) or PCV7 (n= 84) at 2, 4, 6 and 15 months with routine pediatric vaccines.For the 7 PCV13/PCV7 common serotypes, serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) were high 1 month postinfant series, with ≥95.0% in both groups achieving IgG levels ≥0.35 μg/mL, with a trend to lower IgG GMCs for PCV13 compared with PCV7 (PCV13:PCV7 GMC ratios 0.59-0.91). For the 6 additional serotypes unique to PCV13, GMCs were notably higher after PCV13 than PCV7 (PCV13:PCV7 GMC ratios 1.50-202.58). Immune responses generally increased posttoddler dose. Safety was similar between groups.PCV13 was safe and immunogenic in this Taiwanese population. PCV13 should offer broader protection than PCV7 against pneumococcal disease.Clinical trials registration number: NCT00688870.

Original languageEnglish
Pages (from-to)2054-2059
Number of pages6
JournalVaccine
Volume30
Issue number12
DOIs
Publication statusPublished - Mar 9 2012
Externally publishedYes

Fingerprint

Conjugate Vaccines
immunoglobulin G
Taiwan
serotypes
Vaccines
Immunoglobulin G
immune response
Pediatrics
vaccines
Safety
Pneumococcal Vaccines
Double-Blind Method
Multicenter Studies
clinical trials
Clinical Trials
dosage
Population
Serogroup
13-valent pneumococcal vaccine

Keywords

  • Immunogenicity
  • PCV13
  • PCV7
  • Safety
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. / Huang, Li Min; Lin, Tzou Yien; Juergens, Christine.

In: Vaccine, Vol. 30, No. 12, 09.03.2012, p. 2054-2059.

Research output: Contribution to journalArticle

@article{b96a381b12954846b9d154b29a9c7c68,
title = "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan",
abstract = "Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.In this double-blind, multicenter study, healthy children were randomly assigned to receive PCV13 (n= 84) or PCV7 (n= 84) at 2, 4, 6 and 15 months with routine pediatric vaccines.For the 7 PCV13/PCV7 common serotypes, serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) were high 1 month postinfant series, with ≥95.0{\%} in both groups achieving IgG levels ≥0.35 μg/mL, with a trend to lower IgG GMCs for PCV13 compared with PCV7 (PCV13:PCV7 GMC ratios 0.59-0.91). For the 6 additional serotypes unique to PCV13, GMCs were notably higher after PCV13 than PCV7 (PCV13:PCV7 GMC ratios 1.50-202.58). Immune responses generally increased posttoddler dose. Safety was similar between groups.PCV13 was safe and immunogenic in this Taiwanese population. PCV13 should offer broader protection than PCV7 against pneumococcal disease.Clinical trials registration number: NCT00688870.",
keywords = "Immunogenicity, PCV13, PCV7, Safety, Streptococcus pneumoniae",
author = "Huang, {Li Min} and Lin, {Tzou Yien} and Christine Juergens",
year = "2012",
month = "3",
day = "9",
doi = "10.1016/j.vaccine.2011.12.054",
language = "English",
volume = "30",
pages = "2054--2059",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan

AU - Huang, Li Min

AU - Lin, Tzou Yien

AU - Juergens, Christine

PY - 2012/3/9

Y1 - 2012/3/9

N2 - Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.In this double-blind, multicenter study, healthy children were randomly assigned to receive PCV13 (n= 84) or PCV7 (n= 84) at 2, 4, 6 and 15 months with routine pediatric vaccines.For the 7 PCV13/PCV7 common serotypes, serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) were high 1 month postinfant series, with ≥95.0% in both groups achieving IgG levels ≥0.35 μg/mL, with a trend to lower IgG GMCs for PCV13 compared with PCV7 (PCV13:PCV7 GMC ratios 0.59-0.91). For the 6 additional serotypes unique to PCV13, GMCs were notably higher after PCV13 than PCV7 (PCV13:PCV7 GMC ratios 1.50-202.58). Immune responses generally increased posttoddler dose. Safety was similar between groups.PCV13 was safe and immunogenic in this Taiwanese population. PCV13 should offer broader protection than PCV7 against pneumococcal disease.Clinical trials registration number: NCT00688870.

AB - Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.In this double-blind, multicenter study, healthy children were randomly assigned to receive PCV13 (n= 84) or PCV7 (n= 84) at 2, 4, 6 and 15 months with routine pediatric vaccines.For the 7 PCV13/PCV7 common serotypes, serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) were high 1 month postinfant series, with ≥95.0% in both groups achieving IgG levels ≥0.35 μg/mL, with a trend to lower IgG GMCs for PCV13 compared with PCV7 (PCV13:PCV7 GMC ratios 0.59-0.91). For the 6 additional serotypes unique to PCV13, GMCs were notably higher after PCV13 than PCV7 (PCV13:PCV7 GMC ratios 1.50-202.58). Immune responses generally increased posttoddler dose. Safety was similar between groups.PCV13 was safe and immunogenic in this Taiwanese population. PCV13 should offer broader protection than PCV7 against pneumococcal disease.Clinical trials registration number: NCT00688870.

KW - Immunogenicity

KW - PCV13

KW - PCV7

KW - Safety

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84857359989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857359989&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.12.054

DO - 10.1016/j.vaccine.2011.12.054

M3 - Article

C2 - 22198517

AN - SCOPUS:84857359989

VL - 30

SP - 2054

EP - 2059

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -